JOURNAL ARTICLE
MULTICENTER STUDY

Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months

Kenneth Rockwood, Dingwei Dai, Arnold Mitnitski
International Journal of Geriatric Psychiatry 2008, 23 (2): 207-14
17621382

BACKGROUND: Lacking long-term placebo-controlled trials of cholinesterase inhibitors (ChEIs) in Alzheimer's disease, how decline is modeled is crucial to interpreting the effects of long-term, open-label use. We aimed to: 1) understand changes in cognition and function in people taking galantamine; (2) identify treatment subgroups.

METHODS: This is an open-label long-term extension (up to 48 months) of two placebo-controlled clinical trials from Europe and Canada. At baseline, 240 patients with mild-moderate Alzheimer's disease at baseline had received galantamine continuously for 36 months. The trajectory of scores on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) and the Disability Assessment for Dementia (DAD) was modeled over 48 months. Goodness of fit was compared using normalized residuals and by calculating correlation coefficients between observed and fitted data. Iterative K-means clustering identified subgroups.

RESULTS: Of 240 patients, 51 (21%) withdrew between months 36-48 (nine died and 12 with adverse events). The mean ADAS-Cog worsened from 22.6 (mean)+/-8.6 (SD) at baseline to 31.3+/-3.1, with similar changes in the DAD. The logistic function fit better (ADAS-Cog norm of residuals=2.05, r=0.993; DAD=2.21, r=0.998) than the commonly used Stern equation (ADAS-Cog=4.22, r=0.944; DAD=7.51, r=0.986). K-means clustering identified three stable groups; least decline (n=82), persistent progression (n=75), and an intermediate group (n=82). Initial conditions were important: the mean ADAS-Cog score for those with least decline was 15+/-8, better than both the intermediate group (20+/-9) and persistent progressors (30+/-10; p<0.001).

CONCLUSIONS: Alzheimer's disease patients show variable long-term decline that is best modeled as a logistic function, not as linear decline. Over 48 months, about one-third of patients showed little decline, while one-third showed important decline.

Full Text Links

Find Full Text Links for this Article

Discussion

You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Remove bar
Read by QxMD icon Read
17621382
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"